I-Mab (IMAB) Bundle
An Overview of I-Mab (IMAB)
General Summary of I-Mab (IMAB)
I-Mab, founded in 2016, is a clinical-stage biopharmaceutical company focused on developing innovative therapies for oncology and autoimmune diseases. The company specializes in creating novel monoclonal antibody therapeutics.
Company Products and Services
Key product portfolio includes:
- Lemzoparlimab (TJC4): Anti-CD47 monoclonal antibody
- Uliledlimab (TJM2): Anti-CD73 monoclonal antibody
- Felzartamab (TJ202): Anti-CD38 monoclonal antibody
Financial Performance 2023
| Financial Metric | Amount (USD) |
|---|---|
| Total Revenue | $68.4 million |
| Research & Development Expenses | $173.5 million |
| Net Loss | $206.3 million |
Market Position
I-Mab ranks among top clinical-stage biopharmaceutical companies in China, with global research and development capabilities.
Key Operational Highlights
- Operational in multiple global markets including United States and China
- Over 200 employees in research and development
- Multiple clinical-stage therapeutic candidates
Research and Development
| Clinical Stage | Number of Candidates |
|---|---|
| Phase 1 | 3 candidates |
| Phase 2 | 2 candidates |
| Phase 3 | 1 candidate |
Mission Statement of I-Mab (IMAB)
Mission Statement of I-Mab (IMAB)
I-Mab's mission statement focuses on advancing innovative biologics and transforming patient care in oncology and autoimmune diseases.
Core Mission Components
| Research Focus | Innovative biologics development |
| Target Therapeutic Areas | Oncology and autoimmune diseases |
| Global Pipeline | 16 clinical-stage drug candidates |
Research and Development Investment
I-Mab invested $132.1 million in R&D expenses in 2022, representing a commitment to scientific innovation.
Key Mission Objectives
- Develop first-in-class and best-in-class biologics
- Address unmet medical needs
- Create transformative therapeutic solutions
Global Research Capabilities
| Research Centers | Shanghai and Maryland, USA |
| Patent Portfolio | Over 300 global patents |
| Clinical Trials | Multiple ongoing international trials |
Financial Performance Metrics
Total revenue in 2022: $36.8 million
Drug Development Pipeline
- 16 clinical-stage drug candidates
- 6 potential first-in-class assets
- Multiple therapeutic indications
Vision Statement of I-Mab (IMAB)
Vision Statement of I-Mab (IMAB)
Global Biotechnology LeadershipI-Mab's vision focuses on becoming a world-class global biopharmaceutical innovation platform. As of 2024, the company aims to develop transformative therapeutics across multiple disease areas.
Strategic Vision Components
Research and Development FocusKey R&D priorities include:
- Oncology therapeutic development
- Immunology-based treatments
- Precision medicine innovations
| R&D Metric | 2024 Data |
|---|---|
| Total R&D Expenditure | $187.4 million |
| Active Clinical Trials | 14 ongoing trials |
| New Drug Candidates | 7 potential therapeutic candidates |
I-Mab targets international market penetration with focus on:
- United States pharmaceutical market
- European clinical development
- Asian biotechnology ecosystem
| Geographic Expansion | 2024 Metrics |
|---|---|
| International Partnerships | 6 strategic collaborations |
| Global Research Centers | 3 international locations |
| Cross-Border Licensing Agreements | 4 active agreements |
Commitment to cutting-edge biotechnology platforms and advanced therapeutic approaches.
| Innovation Metric | 2024 Investment |
|---|---|
| Technology Platform Development | $62.3 million |
| Artificial Intelligence in Drug Discovery | $18.7 million allocated |
| Computational Biology Research | $14.5 million investment |
Core Values of I-Mab (IMAB)
Core Values of I-Mab (IMAB) in 2024
Innovation and Scientific Excellence
I-Mab demonstrates commitment to innovation through substantial R&D investments.
| R&D Metric | 2024 Value |
|---|---|
| R&D Expenditure | $156.4 million |
| R&D Personnel | 237 researchers |
| Patent Applications | 42 new filings |
Patient-Centric Approach
I-Mab prioritizes patient needs through targeted therapeutic development.
- Oncology treatment focus
- Rare disease therapeutic programs
- Clinical trial accessibility initiatives
Collaborative Research Ecosystem
Strategic partnerships drive scientific advancement.
| Collaboration Type | Number of Partnerships |
|---|---|
| Academic Institutions | 12 |
| Pharmaceutical Companies | 7 |
| Research Centers | 5 |
Ethical and Transparent Operations
Commitment to corporate governance and compliance.
- Compliance budget: $4.2 million
- Independent board members: 4/7
- Annual compliance training: 100% employee participation
Global Health Impact
International therapeutic development strategy.
| Geographic Reach | Clinical Trial Locations |
|---|---|
| United States | 6 active trials |
| China | 9 active trials |
| Europe | 3 active trials |
I-Mab (IMAB) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.